Yaşlılık Çağında Psikofarmakolojik Yaklaşımlar
Özet
Yaşlılık dönemi, fizyolojik değişimler ve artan kronik hastalıklar nedeniyle genç nüfusa kıyasla daha yoğun ilaç kullanımına sahne olmakta, bu durum psikofarmakolojik yaklaşımlarda son derece hassas bir denge yönetimini zorunlu kılmaktadır. Yaşlanmayla birlikte organ rezervlerinin azalması, karaciğer enzim aktivitelerinin zayıflaması ve böbrek fonksiyonlarındaki gerileme; ilaçların vücuttaki emilim, dağılım, metabolizma ve atılım süreçlerini kapsayan farmakokinetik ile doku duyarlılığını içeren farmakodinamik mekanizmaları doğrudan etkilemektedir. Özellikle sitokrom P450 izoenzimleri üzerindeki ilaç-ilaç ve ilaç-besin etkileşimleri, maddelerin yarılanma sürelerini uzatarak ciddi toksisite risklerine ve aritmi, deliryum gibi yan etkilere yol açabilmektedir. Beş veya daha fazla ilaç kullanımı olarak tanımlanan polifarmasi, yaşlı popülasyonda tedavi uyumunu zorlaştırırken hastaneye yatış oranlarını artırmaktadır. Bu doğrultuda trisiklik antidepresanlar, benzodiazepinler ve lityum gibi dar terapötik aralığa sahip duygudurum düzenleyiciler ile tipik/atipik antipsikotiklerin kullanımı; düşme, kırık, pnömoni ve demans hastalarında mortalite artışı gibi riskler nedeniyle oldukça sınırlandırılmalıdır. Sonuç olarak, yaşlılık çağında psikotrop tedavilere başlanmadan önce hastanın mevcut tüm ilaçları, böbrek klirensi ve beslenme düzeni titizlikle incelenmeli, tedaviye daima en düşük etkin dozla başlanarak süreç yakın takip altında sürdürülmelidir.
The geriatric period experiences more intense drug use compared to the younger population due to physiological changes and increased chronic diseases, which necessitates an extremely delicate balance management in psychopharmacological approaches. The age-related decrease in organ reserves, weakening of liver enzyme activities, and decline in renal functions directly affect pharmacokinetics—encompassing drug absorption, distribution, metabolism, and excretion—as well as pharmacodynamics involving tissue sensitivity. Especially drug-drug and drug-food interactions on cytochrome P450 isoenzymes prolong the half-lives of substances, leading to serious toxicity risks and side effects such as arrhythmia and delirium. Polypharmacy, defined as the use of five or more medications, compromises treatment adherence and increases hospitalization rates in the elderly population. Accordingly, the use of tricyclic antidepressants, benzodiazepines, mood stabilizers with narrow therapeutic windows like lithium, and typical/atypical antipsychotics should be highly restricted due to risks such as falls, fractures, pneumonia, and increased mortality in dementia patients. Consequently, before initiating psychotropic treatments in old age, all current medications, renal clearance, and nutritional status of the patient must be meticulously examined, and the process should always be maintained under close monitoring by starting with the lowest effective dose.
Referanslar
Turnheim K. When drug therapy gets old: pharmacokinetics and pharmacodynamics in the elderly. Exp Geront. 2003;38:843-853.
Mangoni AA, Jackson HD. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol. 2003;57:6-14.
Kratz T, Diefenbacher. Psychopharmacological treatment in older people. Dtsch Arztebl Int. 2019;116:508-518.
Briciu C, Neag M, Muntean D, et al. A pharmacokinetic drug interaction study between nebivolol and paroxetine in healthy volunteers. J Clin Pharm Ther. 2014;39:535-540.
Poulsen L, Arendt-Nielsen L, Brosen K, et al. The hypoalgesic effect of tramadol in relation to CYP2D6. Clin Pharmacol Ther. 1996; 60:636-644.
Flockhart DA, Drici MD, Kerbusch T, et al. Studies on the mechanism of a fatal clarithromycin-pimozide interaction in a patient with tourette syndrome. J Clin Psychopharmacol. 2000;20:317-324.
Etheridge AS, Black SR, Pantel PR, et al. An in vitro evaluation of cytochrome P450 inhibition and P-glycoprotein interaction with goldseal, ginkgo biloba, grape seed, milk thistle, and ginseng extracts and their constituents. Planta Med. 2007;73:731-741.
Unger M. Pharmacokinetic drug interactions involving ginkgo biloba. Drug Metab Rev. 2013;45:353-385.
Hakooz N, Hamdan I. Effects of dietary broccoli on human in vivo caffeine metabolism: a pilot study on a group of Jordanian volunteers. Curr Drug Metab. 2007;8:9-15.
Kaboli PJ, McClimon BJ, Hoth AB. Assessing the accuracy of computerized medication histories. Am J Manag Care. 2004;10:872-877.
Preskorn HS. Comparison of the tolerability of bupropion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline and venlafaxine. J Clin Psychiatry. 1995;56:12-21.
Walraven van C, Mamdam MM, Wells PS, et al. Inhibition of serotonin reuptake by antidepressants and upper gastrointestinal bleeding in elderly patients: retrospective cohort study. Brit J Med. 2001;323:655-658.
Shukla R, Khasbage S, Garg MK, et al. Duloxetine-induced hypertensive urgency in type 2 diabetes mellitus with diabetic neuropathy. Indian J Pharmacol. 2020;52(3):213-215.
Rodrigues-Amorim D, Olivares JM, Spuch C, et al. A systematic review of efficacy, safety, and tolerability of duloxetine. Front. Psychiatry. 2020;11:554899. doi:10.3389/fpsyt.2020.554899.
Raskin J, Wiltse CG, Siegal A. Efficacy of duloxetine on cognition, depression and pain in elderly patients with major depression: 8 week double blind placebo controlled trait. Am J Psychiatry. 2007;164:900-909.
Schatzberg AF, Kremer C, Rodrigues HE, et al. Double blind randomized comparison of mirtazapine and paroxetine in elderly depressed patients. Am J Geriatr Psychiatry. 2002;10:541-550.
Camargos EF, Pandolfi MB, Freitas MPD, et al. Trazodone for the treatment of sleep disorders in dementia: an open-label, observational and review study. Arq Neuropsiquiatr. 2011;69(1):44-49.
Young RC, Gyulai L, Mulsant BH, et al. Pharmacotherapy of bipolar disorder in old age. Am J Ger Psychiatry. 2004;12:342-357.
Armon C, Shin C, Miller P et al. Reversible parkinsonism and cognitive impairment with chronic valproate use. Neurology. 1996;47:626-35.
Perucca E, Aldenkamp A, Tallis R, et al. Role of valproate across the ages. Treatment of epilepsy in the elderly. Acta Neurol Scand. 2006; 114:28-37.
Perucca E, Grimaldi R, Gatti G, et al. Pharmacokinetics of valproic acid in the elderly. Br J Clin Pharmacol. 1984;17:665-669.
Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005; 294:1934-1943.
Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry. 2006; 14:191–210.
Kleijer BC, van Marum RJ, Egberts AC, et al. Risk of cerebrovascular events in elderly users of antipsychotics. J Psychopharmacol. 2009; 23:909-914.
Jeste DV, Blazer D, Casey D, et al. ANCP White Paper: update on use of antipsychotic drugs in elderly persons with dementia. Neuropsychopharmacology. 2008; 33:957-970.
Herrmann N, Lanctôt KL. Do atypical antipsychotics cause stroke? CNS Drugs. 2005; 19:91-103.
Steinberg M, Lyketsos CG. Atypical antipsychotic use in patients with dementia: managing safety concerns. Am J Psychiatry. 2012; 169:900-906.
Trifirò G, Spina E, Gambassi G. Use of antipsychotics in elderly patients with dementia: do atypical and conventional agents have a similar safety profile? Pharmacol Res. 2009; 59:1-12.
Weiden PJ. EPS profiles: the atypical antipsychotics are not all the same. J Psychiatr Pract. 2007; 13:13-24.
Pratt N, Roughead EE, Ramsay E, et al. Risk of hospitalization for hip fracture and pneumonia associated with antipsychotic prescribing in the elderly: a self-controlled case series analysis in an Australian health care claims database. Drug Saf. 2011; 34:567–575.
Wang PS, Schneeweiss S, Avorn J, et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med. 2005;353:2335-2341.
Schneeweiss S, Setoguchi S, Brookhart A, et al. Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients.
Trifirò G, Gambassi G, Sen EF, et al. Association of community-acquired pneumonia with antipsychotic drug use in elderly patients. Ann Intern Med. 2010;152:418-425.
Landi F, Onder G, Cesari M, et al. Psychotropic medications and risk of falls among community-dwelling frail older people: an observational study. J Gerontol. 2005;60:622-626.
